News

In this role, Dr Cheng will be responsible for Gilead’s biometrics, clinical operations, drug safety and public health, project and portfolio management, and regulatory affairs activities, reporting to

Robin Carlstein, senior vice president of advanced wound devices at Smith & Nephew, said: “Smith & Nephew welcomes the appeals court decision that our Versatile 1 negative pressure

This device-based intellectual property has not been used to date in the Celacade System; however, Vasogen has retained rights to this technology for any potential use as it

Since 1998, Dr Morra has been a board member and consultant for various public and private life science companies. Dr Morra has previously served as the president of

The agreement grants Transgenomic exclusive rights in the US and certain international markets to neurodegenerative biomarkers from Power3 Medical, including NuroPro, a proposed diagnostic for Alzheimer’s and Parkinson’s

The company has reported net sales of $5.21 billion in the fourth quarter of 2008 that were essentially flat compared with the fourth quarter of 2007. For the

Dr Berman succeeds Robert Stote, who has been serving as the chief medical officer of Cpex since its spin-off from Bentley Pharmaceuticals in June 2008. Dr Stote, who

The new clinical development offices and expanded workforce will help Covance expedite the execution of clinical studies and build strategic relationships with investigators and sites in countries well

In his role at Quest, Leon held several positions over time, including director of molecular diagnostics, senior director of biotechnology department, and vice president of applied genomics. “We